Euclises Pharmaceuticals, Inc. to Present Preclinical Efficacy Results at American Association for Cancer Research

On April 19, 2016 Euclises Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel COX-2 inhibitors for the treatment of cancer, reported that its Late-Breaking Abstract has been accepted for presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting in New Orleans on April 19, 2016 (Press release, Euclises, APR 19, 2016, View Source [SID:1234511093]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Entitled, "Anti-tumor effects of ECP-1014 in combination with erlotinib in HT-29 xenograft murine colon carcinoma model," the presentation will report the results of key preclinical experiments using Euclises’ COX-2 inhibitor candidate, ECP-1014. The study, conducted in collaboration with Guangzhou Institute of BioMedicine and Health, builds upon recent research demonstrating a role for overactive COX-2 in maintaining an immunosuppressive microenvironment for a variety of tumors, including colorectal and non-small cell lung cancers.

"The epidermal growth factor (EGFR) inhibitor erlotinib is the current standard of care for advanced colorectal cancer," said Dr. Bobby W. Sandage, Jr., Ph.D., CEO of Euclises. "In this preclinical study, we demonstrate a substantial additional benefit in tumor suppression from combining erlotinib with our third-generation COX-2 inhibitor."

"The research to be presented at AACR (Free AACR Whitepaper) strongly validates Euclises’ approach," added Rick Ryan, Ph.D., chairman of Euclises’ board. "These results comprise an important step towards the clinical translation and commercialization of effective COX-2 inhibitors for colorectal cancer patients."

Dr. Sandage will present the research on Tuesday morning, April 19, in Section 11 of the Late-Breaking Research: Experimental and Molecular Therapeutics 3 poster session.